Survodutide vs Cartalax
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideAnti-Aging & Longevity
Cartalax- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
- Half-Life
- ~7 days
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 10 mg per day
- Frequency
- Once weekly
- Daily for 10–30 days
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Supports cartilage matrix synthesis and maintenance
- May slow progression of osteoarthritic cartilage degradation
- Reduces chondrocyte apoptosis
- Promotes joint longevity in aging and high-impact sports
- Anti-aging effects on connective tissue
- Complementary to BPC-157 and TB-500 in joint recovery protocols
- Well tolerated in available human and animal research
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Generally well tolerated
- Mild injection site reactions
- No significant adverse events reported at standard doses
- Stacks With
- —
- —